Vegetable oil-based hybrid microparticles as a green and biocompatible system for subcutaneous drug delivery
[Display omitted] •Design of a green process to produce vegetable oil-based hybrid microparticles.•Preservation of the biological activity of the loaded estradiol after process.•One week- release profile evaluated in a biphasic system.•Fully biocompatible drug delivery system for subcutaneous admini...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2021-01, Vol.592, p.120070-120070, Article 120070 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
•Design of a green process to produce vegetable oil-based hybrid microparticles.•Preservation of the biological activity of the loaded estradiol after process.•One week- release profile evaluated in a biphasic system.•Fully biocompatible drug delivery system for subcutaneous administration.
The aim of this study was to evidence the ability of vegetable oil-based hybrid microparticles (HMP) to be an efficient and safe drug delivery system after subcutaneous administration. The HMP resulted from combination of a thermostabilized emulsification process and a sol–gel chemistry. First of all, castor oil was successfully silylated by means of (3-Isocyanatopropyl)trimethoxysilane in solvent-free and catalyst-free conditions. Estradiol, as a model drug, was dissolved in silylated castor oil (ICOm) prior to emulsification, and then an optimal sol–gel crosslinking was achieved inside the ICOm microdroplets. The resulting estradiol-loaded microparticles were around 80 µm in size and allowed to entrap 4 wt% estradiol. Their release kinetics in a PBS/octanol biphasic system exhibited a one-week release profile, and the released estradiol was fully active on HeLa ERE-luciferase ERα cells. The hybrid microparticles were cytocompatible during preliminary tests on NIH 3T3 fibroblasts (ISO 10993-5 standard) and they were fully biocompatible after subcutaneous injection on mice (ISO 10993-6 standard) underlining their high potential as a safe and long-acting subcutaneous drug delivery system. |
---|---|
ISSN: | 0378-5173 1873-3476 |
DOI: | 10.1016/j.ijpharm.2020.120070 |